Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02367833 · ClinicalTrials.gov registry record · Phase 4
Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis
A Phase 4 study, sponsored by Penn State University.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT02367833 is a Phase 4 study that has completed, run by Penn State University. The registered enrollment target is 60 participants.
The verdict
NCT02367833, a Phase 4 study, has completed, sponsored by Penn State University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study will determine whether the negative effects of combined oral contraceptive (COC) therapy on the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis and bone turnover are dependent on the route of administration such that an attenuation of these effects is observed when a comparable dose of non-oral transdermal contraceptive (TDC) and contraceptive vaginal ring therapy (CVR) are also tested.
Interventions
- DRUG Combined Oral Contraceptive
- DRUG Transdermal Contraceptive
- DRUG Contraceptive Vaginal Ring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-01 |
| Est. Completion | 2018-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02367833
The ClinicalTrials.gov registry entry for NCT02367833 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Penn State University, which has 219 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Combined Oral Contraceptive is the first listed.
NCT02367833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02367833 about?
NCT02367833 is a clinical study titled "Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis". This study will determine whether the negative effects of combined oral contraceptive (COC) therapy on the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis and bone turnover are dependent on the route of administration such that an attenuation of these effects is observed when a comparabl...
What is the current status of trial NCT02367833?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2015-01. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02367833?
The interventions under investigation include: Combined Oral Contraceptive (DRUG), Transdermal Contraceptive (DRUG), Contraceptive Vaginal Ring (DRUG).
Who is sponsoring clinical trial NCT02367833?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.